Navigation Links
Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
Date:6/22/2009

SAN DIEGO, June 22 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that Scott Byrd has joined the company as Senior Vice President and Chief Commercial Officer. Mr. Byrd will report directly to Ted Schroeder, President and Chief Executive Officer, and his responsibilities will include sales, marketing, and supply operations.

Mr. Byrd joins Cadence from Eli Lilly and Company (Lilly) where he held positions of increasing responsibility over the last seventeen years and was most recently U.S. Brand Leader, Prasugrel. In that capacity, he was responsible for all commercial planning and marketing activities in the United States in preparation for the planned launch of prasugrel. Previously, he was Senior Director, Global Brands, Cardiovascular and Acute Care where he led global commercial strategy development for Lilly's cardiovascular and acute care products, including prasugrel, ReoPro(R), Xigris(R), and various development stage compounds. Mr. Byrd also served as Director, Sales and Marketing, Cardiovascular Business Unit where he directly managed U.S. sales and marketing activities related to ReoPro. He has held a number of other positions of increasing responsibility at Lilly in commercial, finance, manufacturing, and strategic planning roles. Mr. Byrd holds a B.S. in mechanical engineering from Bradley University and an M.B.A. from Harvard Business School.

"We are very pleased to have Scott join the executive team at Cadence," said Ted Schroeder, President and Chief Executive Officer of Cadence. "We believe that his extensive sales and marketing background in the acute care area and his pre-launch experience with prasugrel will be a significant asset to Cadence as we prepare to commercialize Acetavance(TM), for which we submitted a New Drug Application to the FDA
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
4. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
5. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
7. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
10. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
11. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 On October ... Minds featuring skin diseases both fictional and real. ... (CEHMDF), a nonprofit organization committed to advocacy and philanthropy ... CBS will take the opportunity to impart truth and ... , There are many misconceptions about Morgellons ...
(Date:10/22/2014)... For Dr. Iris Hunter, a job is ... extension of her life’s mission. Her extensive experience in the ... of FirstLight HomeCare, make it clear that Hunter’s mission is ... my work makes a difference in the lives of others,” ... after much research, I felt ready to start on this ...
(Date:10/22/2014)... Kentucky (PRWEB) October 22, 2014 Shriners ... agreement that will change the current location of Shriners ... to South Limestone across from the University of Kentucky ... a state-of-the-art ambulatory care center, owned and operated by ... the orthopaedic needs of children and their families well ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2
... & Ellis Company on REIT,s Growth Strategies, SANTA ANA, ... announced that Scott D. Peters will continue to serve as,Chairman ... Grubb &,Ellis Healthcare REIT following his resignation as Chief Executive ... am excited to be able to devote a greater degree ...
... study finds , , FRIDAY, July 11 (HealthDay News) -- People ... taking beta blockers should be kept on those medications while ... they weren,t taking beta blockers already, most of them should ... a report in the July 15 issue of the ...
... $850 million in cuts, WASHINGTON, July 11 ... important benefits and pay more out of,pocket for ... Medicare,Advantage plan altogether under legislation approved this week ... would cut nearly $14 billion from the,Medicare Advantage ...
... alcohol use, or binge drinking, among college students in the ... That is one of the key findings from research conducted ... Alcohol Study (CAS), a landmark study that surveyed more than ... a new review that examines the findings from the CAS ...
... Funds dedicated to Nursing,Homes, NEW YORK, July 11 ... mixed results and promising signs among state,government efforts to ... report, only four states spent more than 50 percent ... and community,based services. In New York State, 74% of ...
... Four Dogs Die of Cancer ... 2 MAF Canine Cancer Campaign Seeking ... and lovers in the United,States view canine cancer as the greatest health ... of cancer. Cancer is the,number one cause of death in dogs over ...
Cached Medicine News:Health News:Scott D. Peters to Continue as Chairman and CEO of Grubb & Ellis Healthcare REIT 2Health News:Scott D. Peters to Continue as Chairman and CEO of Grubb & Ellis Healthcare REIT 3Health News:Beta Blockers Help Hospitalized Heart Failure Patients 2Health News:Pennsylvania Seniors' Medicare Advantage Benefits at Risk 2Health News:Binge drinking tied to conditions in the college environment 2Health News:Binge drinking tied to conditions in the college environment 3Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 2Health News:New AARP Report Finds Mixed Results Among State Governments' Efforts to Balance Long Term Care Services Under Medicaid 3Health News:Canine Cancer #1 Fear of Dog Lovers; Web Exclusive By Morris Animal Foundation Provides News on Latest Breakthroughs - Crucial Facts for Dog Owners 2
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... , Oct. 20, 2014  Indianapolis interventional medical ... Toronto -based 3D visualization leader ... of Neurological Surgeons Annual Meeting that they have ... brain surgery. The collaboration is the first of ... to improve patient outcomes. NICO,s BrainPath® interventional access ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... Pharmaceuticals, Inc., (NASDAQ: ACRX ) ("AcelRx"), a ... of innovative therapies for the treatment of acute and ... patent granted by the European Patent Office expired on ... that the patent has been opposed. The patent (European ...
... China, May 9, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... a leading pharmaceutical company specializing in the development, manufacturing, ... announced today that the Company filed its annual report ... 2010 with the Securities and Exchange Commission on May ...
Cached Medicine Technology:AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period 2AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period 3
... system's curved-on-curved articulation maintains full inter-changeability. ... options for better patient fit. The ... spray porous coating, which offers an ... processed polyethylene is used for consistent, ...
... of posterior stabilized knee has an ... Patellar flange mates with both resurfacing ... assure precise, repeatable kinematics and fit ... to reduce wear. Constant cutting guide ...
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
Medicine Products: